Targeting ErbB3 Receptor in Cancer with Inhibitory Antibodies from Llama

Targeting ErbB3 Receptor in Cancer with Inhibitory Antibodies from Llama

The human ErbB3 receptor confers resistance to the pharmacological inhibition of EGFR and HER2 receptor tyrosine kinases in cancer, which makes it an important therapeutic target. Several anti-ErbB3 monoclonal antibodies that are currently being developed are all classical immunoglobulins. We took a...

Full description

Bibliographic Details
Main Authors: Igor E. Eliseev, Valeria M. Ukrainskaya, Anna N. Yudenko, Anna D. Mikushina, Stanislav V. Shmakov, Anastasiya I. Afremova, Viktoria M. Ekimova, Anna A. Vronskaia, Nickolay A. Knyazev, Olga V. Shamova
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Biomedicines
Subjects:
cancer therapy
monoclonal antibodies
receptor tyrosine kinases
HER3
antibody purification
conformational stability
Online Access:https://www.mdpi.com/2227-9059/9/9/1106

Internet

https://www.mdpi.com/2227-9059/9/9/1106

Similar Items